ClinicalTrials.gg
TerminatedNCT03711279Updated Feb 29, 2024Results posted

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

A Phase 2 interventional study of SHR-1210 plus Apatinib and ADM plus IFO or IFO alone in Sarcoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Terminated at 1 site in China. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor R \& D Strategy Adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing apatinib in Sarcoma — 3 open to participants now, 3 under way, none of them phase 3. apatinib · Sarcoma.

Enrollment
4th of 13
99 · median 60
Started
2018
with 1 other
Phase 2
12 of 13
2 open now
Registered
5th of 13
by date
Lead sponsor
1 of 13
Jiangsu HengRui Medicine Co., Ltd.

Among the 13 studies testing apatinib in Sarcoma, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is one of 12 in phase 2, and was the 5th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

3 of the 13 studies testing apatinib in Sarcoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing apatinib in Sarcoma, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy of SHR-1210 plus Apatinib versus AMD plus IFO in participants with soft tissue sarcoma.

03

Conditions studied

  • Sarcoma

Browse trials for

Keywords

  • Sarcoma
  • SHR-1210
  • Apatinib
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with the age from 16 years to 70 years.
  • (ECOG) performance status of 0 or 1;the ECOG performance status of 2 can be accepted after the amputation.
  • of at least 3 months.
  • confirmed diagnosis of advanced unresectable or soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.The histopathologic types as specified in the protocol.
  • Without prior systemic chemotherapy or relapse more than 6 months after the completion of last systemic chemotherapy.
  • Presence of as defined by the (RECIST 1.1).
  • Acceptable liver function, renal function, hematologic status and coagulation function as specified in the protocol.
  • Females of must have a negative serum pregnancy test within 7 days prior to randomization.Females of child-bearing potential and males must agree to use highly effective precautions during the trial and up to 3 months following the last dose of study drug.
  • Willingness to comply with the study protocol for any reason.

Exclusion criteria

Exclusion Criteria:

  • Receiving any previous anticancer treatment, other drugs or any attenuated with 4 weeks of the first does of study drug.
  • Prior treatment with /PD-L1/CTLA-4 targeted drugs or VEGFR targeted drugs.
  • Plan to receive surgery or radiotherapy to treat the sarcoma during the trail.
  • Radiological evidence of or primary tumors.
  • Diagnosed other within the last 3 years from the first dose of drug.
  • Known allergy to any of the treatment components.
  • Active infection including (HIV) , or .
  • Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    SHR-1210 plus Apatinib

    Drug: SHR-1210 plus Apatinib

  • Active comparator
    ADM plus IFO or IFO alone

    Drug: ADM plus IFO or IFO alone

Interventions

  • DrugSHR-1210 plus Apatinib

    Drug pages: Camrelizumab · Apatinib

    SHR-1210 200 mg q3w+ Apatinib 500 mg qd

    Also known as: PD-1 antibody + Anti-angiogenesis

  • DrugADM plus IFO or IFO alone

    ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w;if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.

    Also known as: chemotherapy

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Randomization to Radiographic Progression or Death Due to Any Cause (Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 31 months, CT was conducted at baseline、weeks 7、13、19 and then every 12 weeks.

Secondary outcomes

  1. Objective Response Rate (ORR)

    Baseline to documented disease Remission to study discontinuation, Partial Remission is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 30% decrease in the sum of the beaseline diameter of target lesions.

    Time frame: From date of randomization until the date of study completion, an average of 1 year, CT was conducted at baseline、weeks 7、13、19 and then every 12 weeks.

07

Results

Posted Feb 29, 2024

Participant flow

Participant flow — Overall Study
MilestoneSHR-1210 Plus ApatinibADM Plus IFO or IFO Alone
Started5148
Completed5047
Not completed11

Outcome measures

PrimaryProgression Free Survival (PFS)

Randomization to Radiographic Progression or Death Due to Any Cause (Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 31 months, CT was conducted at baseline、weeks 7、13、19 and then every 12 weeks.
Reported as:
Median · months
Progression Free Survival (PFS)
monthsSHR-1210 Plus ApatinibADM Plus IFO or IFO Alone
Progression Free Survival (PFS)5.6 (4.1 to 6.9)5.5 (3.5 to 8.4)
SecondaryObjective Response Rate (ORR)

Baseline to documented disease Remission to study discontinuation, Partial Remission is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 30% decrease in the sum of the beaseline diameter of target lesions.

Time frame:
From date of randomization until the date of study completion, an average of 1 year, CT was conducted at baseline、weeks 7、13、19 and then every 12 weeks.
Reported as:
Number · participants
Objective Response Rate (ORR)
participantsSHR-1210 Plus ApatinibADM Plus IFO or IFO Alone
Objective Response Rate (ORR)115

Adverse events

Collected over 18 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SHR-1210 Plus Apatinib2/50 (4%)27/50 (54%)50/50 (100%)
ADM Plus IFO or IFO Alone2/47 (4.3%)13/47 (27.7%)45/47 (95.7%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventSHR-1210 Plus ApatinibADM Plus IFO or IFO Alone
AnemiaBlood and lymphatic system disorders1/506/47
White blood cell count decreasedInvestigations0/505/47
Neutrophil count decreasedInvestigations0/505/47
Alanine aminotransferase increasedInvestigations5/500/47
Platelet count decreasedInvestigations0/504/47
Aspartate aminotransferase increasedInvestigations4/500/47
Drug-induced liver injuryHepatobiliary disorders3/500/47
PyrexiaGeneral disorders3/501/47
Lymphocyte count decreasedInvestigations0/502/47
Febrile neutropeniaBlood and lymphatic system disorders0/502/47
Most frequent other events
Showing 10 of 97
Most frequent other events
EventSHR-1210 Plus ApatinibADM Plus IFO or IFO Alone
AnaemiaBlood and lymphatic system disorders21/5034/47
Aspartate aminotransferase increasedInvestigations33/509/47
Alanine aminotransferase increasedInvestigations31/5016/47
ProteinuriaRenal and urinary disorders29/503/47
HypertensionVascular disorders29/501/47
White blood cell count decreasedInvestigations28/5024/47
Lymphocyte count decreasedInvestigations19/5026/47
Platelet count decreasedInvestigations26/5018/47
DiarrhoeaGastrointestinal disorders25/503/47
Gamma-glutamyltransferase increasedInvestigations25/508/47

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SHR-1210 Plus ApatinibADM Plus IFO or IFO AloneTotal
<=18 years011
Between 18 and 65 years494190
>=65 years156
Sex: Female, Male
Sex: Female, Male(Participants)SHR-1210 Plus ApatinibADM Plus IFO or IFO AloneTotal
Female202040
Male302757
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SHR-1210 Plus ApatinibADM Plus IFO or IFO AloneTotal
American Indian or Alaska Native000
Asian504797
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)SHR-1210 Plus ApatinibADM Plus IFO or IFO AloneTotal
China504797
08

Study locations

1 site
  • Shanghai Jiao Tong University Affiliated Sixth People's Hospital
    Shanghai, Shanghai, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Jun 2021, 30 months.

Results were first posted in Feb 2024, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2018
First posted
Oct 18, 2018
StartActual
Nov 22, 2018
Primary completionActual
Jun 21, 2021
CompletionActual
Jun 21, 2021
Results first posted
Feb 29, 2024
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03711279
Responsible party
Sponsor
First posted
Oct 18, 2018
Start date
Nov 22, 2018
Primary completion
Jun 21, 2021
Completion
Jun 21, 2021
Results posted
Feb 29, 2024
Last update
Feb 29, 2024

Study contacts

Yang Yao, M.D.
principal investigator · Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Apatinib

Start the discussion